FENC

Over the past six months, Fennec's stock has been impacted by several events. Record annual revenue for FY2025 and Q4 2025 net product sales were reported, but the stock dropped due to concerns about profitability and dilution. Inducement grants led to a stock price increase. An investigator-sponsored study announcement resulted in a stock price decrease. The acceptance of abstracts at the ASCO Annual Meeting led to a stock price increase. The announcement of the Q1 2026 earnings release saw a positive move. An underwritten registered public offering of common shares was priced, with net proceeds intended for debt repurchase, working capital, and general corporate purposes. Fennec paid down debt, resulting in no debt outstanding as of December 31, 2025.